A new lawsuit against the White House is challenging federal laws on cannabis and its medical application in the US. Last week (February 14) arguments were presented for Washington, et.al v. Sessions, a New York case in which the plaintiffs are seeking an update to the major barrier for the full legalization of the drug.

Despite previous similar hearings held across the country, this particular case is gaining momentum thanks to its collection of plaintiffs. The formal lawsuit was filed last year in the Federal District Court in Manhattan and places the Department of Justice, Attorney General Jeff Sessions and the DEA as the defendants for the case.

Alexis Bortell is a 12-year-old girl dealing with epilepsy using a cannabis treatment and one of the plaintiffs at the center of this case. She argued for her right to travel with medicinal cannabis between states and into ones where the drug remains illegal. Jager Cotte

From the remaining five plaintiffs, they include Marvin Washington, a former football player arguing for his right to conduct cannabis-related business in between states. Jager Cotte, another pediatric cannabis patient. The Cannabis Cultural Association (CCA), a nonprofit focused on aiding marginalized communities in the industry, and Jose Belen an Army veteran using cannabis to treat his PTSD.

Advocates hopeful thanks to sympathetic comment from Judge

According to NORML, an advocacy group seeking to change federal marijuana laws, Judge Alvin K. Hellerstein of the U.S. District Court for the Southern District of New York showed sympathy for the plaintiffs by asking how anyone could say their lives had not “been saved by marijuana.”

However, Hellerstein agreed with the government’s argument that “the plaintiffs have not petitioned the Drug Enforcement Agency to reclassify marijuana,” a report from the Associated Press said last Wednesday.

“The lawsuit claims that the government’s decision to classify marijuana as dangerous is irrational, unconstitutional and motivated by politics,” the report said.

On the government’s side, Justice Department lawyers requested the case to be dismissed based on the current federal stance against marijuana.

“Because such a right is not ‘implicit in the concept of ordered liberty’ or ‘deeply rooted in this Nation’s history,’ the Court should reject such a claim,” NORML wrote.

Cannabis remains illegal under the federal system in the US in accordance with the Controlled Substance Act. The Act catalogs the plant as a Schedule I drug, “the most restrictive category reserved for the most dangerous narcotics,” the New York Times wrote.

CCA co-founder and deputy director Jake Plowden told Cannabis Now this case could represent the actual de-scheduling of cannabis as a Schedule I drug and “ultimately ending global cannabis prohibition.”

This case picked up steam from the decision by Sessions to rescind Obama-era guidance protecting the cannabis industry. The uncertainty of the market was increased last month when Sessions introduced his own memorandum allowing federal prosecutors to use their law against cannabis companies if they deemed it so.

Since the change in policy, there hasn’t been a crackdown on companies operating in the States. However, public companies in Canada had to provide an update on their risk disclosures to potential shareholders.

Investor Takeaway

As this case continues to gain prominence, there could be developments affecting the laws in the US, a country holding some of the biggest markets available.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Centurion to acquire a Disruptive Water-Soluble Cannabinoid Technology Platform Delivering Rapid Onset, Increased Bioavailability, Premium Taste Profiles and Highly Competitive Cost Structure

Centurion Minerals Ltd. (TSXV: CTN) (FSE: XJCB) (“Centurion” or the “Company”) is pleased to announce that it has entered into an Amalgamation Agreement dated February 17, 2021 (the “Agreement”), with HAI Beverages Inc. (“HAI”), whereby Centurion will acquire 100% of the outstanding shares and assets of a wholly-owned subsidiary of HAI (“NewHAI) in exchange for common shares of Centurion (the “Acquisition” or “Transaction”). NewHAI holds all material assets of HAI and the Acquisition will constitute a reverse take-over (“RTO”) of the Company.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less